Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

AGILENT

Agilent provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling... read more Featured Products: More products

Download Mobile App




PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

By LabMedica International staff writers
Posted on 27 Jul 2026

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumors express PD-L1 and who may be eligible for treatment with KEYTRUDA (pembrolizumab), Merck’s anti‑PD‑1 therapy. More...

The certification expands access to PD‑L1 testing that supports informed treatment decisions in a disease area where options remain limited. This marks the eighth CE‑marked companion diagnostic indication currently available for PD‑L1 IHC 22C3 pharmDx (Code SK006) in the EU.

The assay enables pathologists to assess PD‑L1 expression in tumor tissue to determine patient eligibility for pembrolizumab in accordance with the approved product labeling. By standardizing PD‑L1 immunohistochemistry readouts specific to this setting, laboratories can integrate the assay into routine workflows that inform therapy selection. The indication is designed to align results interpretation with clinical decision points associated with KEYTRUDA use.

PD‑L1 expression in epithelial ovarian, fallopian tube, or primary peritoneal carcinoma was evaluated using PD‑L1 IHC 22C3 pharmDx (Code SK006) in the KEYNOTE‑B96/ENGOT‑ov65 clinical trial, supporting its use as an aid in identifying patients who may be eligible for pembrolizumab in the platinum‑resistant setting. Beyond the new indication, the assay is also indicated in the EU to help physicians identify patients with non‑small cell lung cancer, esophageal cancer, cervical cancer, head and neck squamous cell carcinoma, triple‑negative breast cancer, gastric or gastroesophageal junction adenocarcinoma, and urothelial carcinoma who may be eligible for treatment with KEYTRUDA, in accordance with approved labeling. 

“Expanding access to precision oncology across regions is essential to improving patient outcomes,” said Majken Nielsen, vice president and general manager of Agilent’s Clinical Diagnostics Division. “This EU approval builds on our commitment to deliver high-quality companion diagnostics and enables laboratories to support more informed treatment decisions for patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma.


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Measuring six variants from one sample may improve research efficiency and support clinical trials of amyloid biology in Alzheimer’s disease and related conditions (Image Credit: Adobe Stock)

Plasma Assay Measures Six Amyloid Beta Peptides for Alzheimer’s Treatment Research

Alzheimer’s disease research and related neurological studies often require tools that can characterize brain amyloid pathology and amyloid beta biology. Blood-based biomarker assays may help researchers... Read more

Molecular Diagnostics

view channel
Image: A new study links broad genomic sequencing before first-line therapy to longer survival, supporting its role in treatment decisions (Image Credit: Shutterstock)

Study Supports Broad Genomic Profiling Before First-Line Lung Cancer Treatment

Biomarker testing plays a critical role in advanced non-small cell lung cancer by identifying patients who may benefit from targeted therapies. However, testing only one or two genes can miss actionable... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image Credit: iStock

C2N Makes PrecivityAD2 Alzheimer’s Blood Test Available to Clinicians

Diagnosing Alzheimer’s disease can be challenging, particularly in patients with mild cognitive impairment or early dementia. Assessing brain amyloid pathology can guide clinical decisions, but diagnostic... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.